Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer (NCT06849518)
🩺 Plain-English Summary (8th-Grade Level)
This is a prospective pilot study to assess dynamic changes of plasma cell-free RNA (cfRNA) PD-L1 expression in patients with lung cancer undergoing immune checkpoint inhibitor (ICI) based therapy. Results will be correlated with radiographic assessment of immunotherapy treatment response and plasma NGS ctDNA.
Who can join: Review the eligibility criteria below.
Location: Ballad Health Cancer Care — Kingsport, Tennessee
🧪 Interventions in This Study
- Circulogene liquid biopsy testing (DIAGNOSTIC_TEST)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Ballad Health Cancer Care — Kingsport, Tennessee
📞 Contact the Study Coordinator
Phone: (423) 431-5654
Email: Charles.Mays@balladhealth.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lung Cancer (NSCLC)
- GCC 2545- Improving Post-Radiotherapy Respiratory Function Through Sparing Serial and Parallel Components in the Lung — Baltimore, Maryland
- Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 — Detroit, Michigan
- A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors — Orlando, Florida
- A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation. — Cincinnati, Ohio
- Engagement of Veterans With Lung Cancer — Palo Alto, California
Explore by condition: All Lung Cancer (NSCLC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.